Key Considerations regarding the Renal Risks of Iodinated Contrast Media: The Nephrologist's Role.

IF 2.4 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiorenal Medicine Pub Date : 2023-01-01 Epub Date: 2023-09-27 DOI:10.1159/000533282

Ravindra Mehta, David Sorbo, Federico Ronco, Claudio Ronco

{"title":"Key Considerations regarding the Renal Risks of Iodinated Contrast Media: The Nephrologist's Role.","authors":"Ravindra Mehta, David Sorbo, Federico Ronco, Claudio Ronco","doi":"10.1159/000533282","DOIUrl":null,"url":null,"abstract":"Background: The administration of iodinated contrast medium during diagnostic and therapeutic procedures has always been associated with the fear of causing acute kidney injury (AKI) or an exacerbation of chronic kidney disease. This has led, on the one hand, to the deterrence, when possible, of the use of contrast medium (preferring other imaging methods with the risk of loss of diagnostic power), and on the other hand, to the trialling of multiple prophylaxis protocols in an attempt to reduce the risk of kidney injury.Summary: A literature review on contrast-induced (CI)-AKI risk mitigation strategies was performed, focussing on the recognition of individual risk factors and on the most recent evidence regarding prophylaxis.Key messages: Nephrologists can contribute significantly in the CI-AKI context, from the early stages of the decision-making process to stratifying patients by risk, individualising prophylaxis measures based on the risk profile, and ensuring appropriate evaluation of kidney function and damage post-procedure to improve care.","PeriodicalId":9584,"journal":{"name":"Cardiorenal Medicine","volume":" ","pages":"324-331"},"PeriodicalIF":2.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664334/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiorenal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000533282","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The administration of iodinated contrast medium during diagnostic and therapeutic procedures has always been associated with the fear of causing acute kidney injury (AKI) or an exacerbation of chronic kidney disease. This has led, on the one hand, to the deterrence, when possible, of the use of contrast medium (preferring other imaging methods with the risk of loss of diagnostic power), and on the other hand, to the trialling of multiple prophylaxis protocols in an attempt to reduce the risk of kidney injury.

Summary: A literature review on contrast-induced (CI)-AKI risk mitigation strategies was performed, focussing on the recognition of individual risk factors and on the most recent evidence regarding prophylaxis.

Key messages: Nephrologists can contribute significantly in the CI-AKI context, from the early stages of the decision-making process to stratifying patients by risk, individualising prophylaxis measures based on the risk profile, and ensuring appropriate evaluation of kidney function and damage post-procedure to improve care.

查看原文本刊更多论文

关于碘化造影剂肾脏风险的关键考虑因素：肾脏病学家的作用。

背景：在诊断和治疗过程中使用碘化造影剂总是与担心引起急性肾损伤（AKI）或慢性肾脏疾病（CKD）恶化有关。一方面，这导致了在可能的情况下威慑造影剂的使用（更喜欢具有失去诊断能力风险的其他成像方法），另一方面，尝试多种预防方案，以降低肾损伤的风险。综述：对对比剂诱导（CI）-AKI风险缓解策略进行了文献综述，重点是对个体风险因素的认识和有关预防的最新证据。关键信息：肾病学家可以在CI-AKI的背景下做出重大贡献，从决策过程的早期阶段开始，通过按风险对患者进行分层，根据风险状况采取个性化的预防措施，并确保对肾功能和术后损伤进行适当评估，以改善护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiorenal Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-UROLOGY & NEPHROLOGY

CiteScore

5.40

自引率

2.60%

发文量

审稿时长

>12 weeks

期刊介绍： The journal ''Cardiorenal Medicine'' explores the mechanisms by which obesity and other metabolic abnormalities promote the pathogenesis and progression of heart and kidney disease (cardiorenal metabolic syndrome). It provides an interdisciplinary platform for the advancement of research and clinical practice, focussing on translational issues.